DXA Scan Visceral Fat: Results and Health Risks

A DXA scan for visceral fat offers one of the most accurate and practical ways to assess where fat is stored in your body, going well beyond what BMI or waist circumference can reveal. Using two low-dose X-ray beams, a DXA scan distinguishes visceral adipose tissue from subcutaneous fat, providing clinically meaningful data about your cardiometabolic risk. Whether you are managing your weight, investigating metabolic health, or simply want a clearer picture of your body composition, understanding what a DXA scan measures and what your results mean is an important first step.

What is a DXA scan and how does it measure visceral fat?

A DXA scan uses two low-dose X-ray beams to distinguish visceral fat from subcutaneous fat and lean tissue, estimating visceral adipose tissue via validated algorithms applied to the abdominal region.

A DXA (dual-energy X-ray absorptiometry) scan measures visceral fat by using two low-dose X-ray beams at different energy levels to distinguish between bone mineral, lean tissue and fat tissue across the entire body. Originally developed to assess bone density, modern DXA software can now quantify fat stored in specific regions, including the android (abdominal) region where visceral fat accumulates around internal organs such as the liver, pancreas and intestines.

During the scan, you lie flat on a padded table while a detector arm passes slowly over your body. The process is painless, takes roughly 10 to 20 minutes, and involves a very small radiation dose, considerably lower than a standard chest X-ray.^[1] The scanner produces a detailed body composition map, separating fat mass, lean mass and bone mass by region.

Important safety note: DXA uses ionising radiation. If you are pregnant, think you may be pregnant, or are breastfeeding, you should tell the scanning service before your appointment. Non-urgent DXA scans are generally avoided during pregnancy, consistent with standard NHS imaging safety advice.

Visceral fat is reported separately from subcutaneous fat (the fat stored just beneath the skin). This distinction is clinically important because visceral fat is metabolically active in ways that subcutaneous fat is not. DXA software estimates visceral adipose tissue (VAT) volume or mass using validated algorithms applied to the abdominal region of the scan. The specific outputs and reference ranges differ between scanner manufacturers and software versions, so results should always be interpreted using the reference data provided in your own report.

It is worth noting that DXA does not directly visualise individual fat depots in the way that MRI does. Instead, it uses mathematical modelling to estimate visceral fat from the total abdominal fat compartment. Despite this, DXA-derived VAT measurements correlate well with MRI-based reference standards, making it a practical and widely used clinical tool for body composition assessment.^[2][3]

Why does visceral fat matter more than overall body weight?

Visceral fat releases inflammatory cytokines and free fatty acids directly into the portal circulation, driving insulin resistance and cardiometabolic disease risk in ways that BMI cannot detect.

Visceral fat is more strongly linked to cardiometabolic disease risk than overall body weight or body mass index (BMI) because it is metabolically active tissue that releases inflammatory cytokines, free fatty acids and hormones directly into the portal circulation, affecting the liver and other organs.^[4] Two people with identical BMI values can have very different amounts of visceral fat and therefore very different health risk profiles.

Excess visceral fat is associated with an increased risk of several serious conditions, including:^[5]

• Type 2 diabetes, through promotion of insulin resistance

• Cardiovascular disease, including hypertension, dyslipidaemia and atherosclerosis

• Non-alcoholic fatty liver disease (NAFLD), also increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) in recent clinical literature

• Certain cancers, including colorectal and endometrial cancer

• Obstructive sleep apnoea

BMI, by contrast, measures weight relative to height and cannot distinguish between fat mass and lean muscle mass, nor between visceral and subcutaneous fat. A person with a healthy BMI may still carry a clinically significant amount of visceral fat, a pattern sometimes described as metabolically obese normal weight (MONW). Conversely, a muscular individual may have an elevated BMI with very little visceral fat and a low cardiometabolic risk.

Waist circumference offers a simple proxy measure and is recommended by NICE as part of cardiovascular risk assessment. NICE guidance also highlights waist-to-height ratio as a useful complementary measure: a waist-to-height ratio of 0.5 or above is associated with increased cardiometabolic risk in adults. However, neither waist circumference nor waist-to-height ratio can separate visceral from subcutaneous fat. DXA scanning provides a more precise picture, helping clinicians and patients understand where fat is stored and what that means for long-term health, rather than relying solely on weight or BMI as a guide to risk.

Who should consider getting a DXA scan in the UK?

Adults with central adiposity, type 2 diabetes, a family history of cardiovascular disease, or those undergoing weight management treatment are most likely to benefit from a DXA body composition scan.

A DXA scan for visceral fat assessment is most relevant for adults who have risk factors for cardiometabolic disease but whose standard measurements, such as BMI or waist circumference, do not fully capture their metabolic risk. In the UK, DXA body composition scans are available through some NHS services, private clinics and specialist weight management centres. NHS access is typically through a referral, and DXA for body composition assessment is not routinely commissioned in all areas; a GP or specialist can advise on local availability.

Groups who may particularly benefit from a DXA scan include:

• People with a normal or borderline BMI but central adiposity, where waist circumference is elevated despite a healthy overall weight

• Individuals with type 2 diabetes or prediabetes, where understanding visceral fat burden can inform treatment decisions

• Those with a family history of cardiovascular disease or metabolic syndrome

• People undergoing weight management treatment, where tracking changes in body composition over time is more informative than weight alone

• Postmenopausal women, who tend to experience a redistribution of fat towards the abdomen

• People of South Asian, Black African or Black Caribbean heritage, who are known to carry higher cardiometabolic risk at lower BMI thresholds, as recognised by NICE guidance on ethnicity-specific BMI thresholds^[6]

A GP or specialist can advise whether a DXA scan is appropriate for your individual circumstances. Bolt Pharmacy is a GPhC-registered online pharmacy in Great Britain (pharmacies in Northern Ireland are regulated by the PSNI) offering online weight-management consultations, with prescriber review and pharmacist support, where body composition context can inform clinical decisions.

It is important to discuss your results with a clinician who can interpret them alongside your full medical history, rather than acting on a number in isolation.

How accurate is a DXA scan compared to other body fat tests?

DXA is one of the most accurate clinically available methods for visceral fat measurement, correlating strongly with MRI and outperforming BMI, waist circumference and bioelectrical impedance analysis.

DXA scanning is considered one of the most accurate clinically available methods for measuring visceral fat, with MRI and CT scanning regarded as the gold standard reference methods against which DXA is validated. Studies have shown that DXA-derived visceral adipose tissue measurements correlate strongly with MRI-based measurements, making DXA a practical alternative that avoids the cost, time and (in the case of CT) radiation burden of those techniques.

Compared to other commonly used methods, DXA has clear advantages:

• BMI is a crude population-level tool that cannot distinguish fat from muscle or visceral from subcutaneous fat

• Waist circumference is a useful screening measure recommended by NICE but cannot separate fat compartments

• Bioelectrical impedance analysis (BIA), found in many home scales and handheld devices, estimates total body fat but is sensitive to hydration status and is less reliable for regional fat distribution

• Skinfold callipers measure subcutaneous fat only and are highly operator-dependent

• Hydrostatic (underwater) weighing estimates total body density but does not provide regional fat data

DXA does have limitations. Results can vary between different scanner manufacturers and software versions, which means serial scans are most meaningful when performed on the same machine using the same software. Accuracy may also be affected in individuals with very high body weight if they exceed the scanner table's weight limit, which varies by model. If you are concerned about weight limits, check with the scanning service in advance.

Overall, for a combination of accuracy, accessibility, low radiation dose and detailed regional body composition data, DXA represents the most practical high-quality option available outside specialist research settings in the UK.

What do your DXA scan results actually mean for your health?

DXA results report VAT mass or area with risk categories; a clinician interprets these alongside HbA1c, lipid profile, blood pressure and cardiovascular risk scores such as QRISK3.

DXA scan results for visceral fat are typically reported as a visceral adipose tissue (VAT) mass in grams or as a VAT area in square centimetres, and some reports also provide a risk category or percentile relative to age and sex-matched reference populations. Understanding what these numbers mean requires clinical context, as there is no single universally agreed threshold that applies to everyone.

Many DXA software systems flag visceral fat levels above a certain VAT area as associated with increased cardiometabolic risk. The specific threshold used varies by software, population reference data, sex, age and ethnicity, so the figure shown on your report should be interpreted using the reference ranges provided by that system rather than compared to a single universal cut-off. Your clinician will interpret your VAT result alongside other findings, including:

• Fasting glucose or HbA1c, to assess insulin resistance or diabetes risk

• Lipid profile, particularly triglycerides and HDL cholesterol

• Blood pressure

• Liver function tests, if NAFLD or MASLD is a concern

• Cardiovascular risk scores, such as QRISK3, used in UK primary care to estimate 10-year cardiovascular risk^[9]

Your DXA report will also show your total fat mass, lean mass and bone mineral density, each of which carries its own clinical significance. A low lean mass alongside high visceral fat (sometimes called sarcopenic obesity) carries a particularly elevated risk and may influence the type of intervention recommended.

If your results indicate elevated visceral fat, your GP can arrange further investigations and discuss appropriate management. If you experience severe or sudden chest pain, pain spreading to your arm or jaw, breathlessness, or other symptoms that may suggest a cardiac cause, call 999 or go to your nearest A&E immediately. For non-urgent symptoms such as unexplained fatigue, increased thirst or frequent urination, contact your GP for assessment.

How can you reduce visceral fat after getting your results?

Aerobic exercise, reduced refined carbohydrate intake and limiting alcohol are first-line strategies; NICE-recommended medicines such as semaglutide or tirzepatide may be appropriate where lifestyle change is insufficient.

Visceral fat responds well to lifestyle intervention, and even modest reductions in body weight of around 5 to 10 per cent are associated with meaningful decreases in VAT, often disproportionately so compared to subcutaneous fat.^[10] This makes visceral fat one of the more modifiable cardiovascular risk factors available to address through behaviour change.

Evidence-based strategies for reducing visceral fat include:

• Aerobic exercise: Regular moderate-intensity aerobic activity, such as brisk walking, cycling or swimming, is particularly effective at reducing VAT. UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults^[11][12]

• Resistance training: Building lean muscle mass improves insulin sensitivity and supports long-term fat metabolism

• Dietary change: A diet lower in refined carbohydrates, added sugars and ultra-processed foods, and higher in fibre, vegetables and lean protein, is associated with reduced visceral fat accumulation

• Reducing alcohol intake: Alcohol contributes to hepatic and visceral fat deposition; UK Chief Medical Officers' Low Risk Drinking Guidelines advise keeping consumption below 14 units per week^[13]

• Sleep and stress management: Poor sleep and chronic psychological stress are independently associated with elevated cortisol, which promotes visceral fat storage

For individuals where lifestyle change alone is insufficient, NICE-recommended pharmacological treatments may be appropriate. Medicines such as semaglutide (Wegovy, available in doses up to 2.4 mg weekly by injection and 7.2 mg weekly in oral tablet form) and tirzepatide (Mounjaro), which is MHRA-authorised for both type 2 diabetes and chronic weight management, have demonstrated significant reductions in body fat, including visceral fat, in clinical trials.^[14][15] These are prescribed only where clinically appropriate, following assessment by a qualified prescriber, in line with relevant NICE technology appraisals. If you experience suspected side effects from any medicine, you can report them to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Repeat DXA scanning after a period of intervention can objectively track changes in visceral fat, providing more meaningful feedback than weight alone.

Scientific References

1. Patient dose information: guidance.
2. The prediction of visceral fat by dual-energy X-ray absorptiometry in the elderly: a comparison with computed tomography and anthropometry.
3. MRI Based Validation of Abdominal Adipose Tissue Measurements From DXA in Postmenopausal Women.
4. Visceral fat and metabolic inflammation: the portal theory revisited.
5. Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk.
6. Overweight and obesity management (NG246): Identifying and assessing overweight, obesity and central adiposity.
7. Calculate your waist to height ratio.
8. Overweight and obesity management (NG246): Appendix A1 – Summary of evidence from surveillance.
9. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238).
10. Subcutaneous fat loss is greater than visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical review and meta-analysis.
11. Physical activity guidelines: UK Chief Medical Officers' report.
12. Physical activity guidelines for adults aged 19 to 64.
13. Alcohol consumption: advice on low risk drinking.
14. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
15. Tirzepatide.
16. Tirzepatide: a medicine to manage type 2 diabetes and obesity.
17. Tirzepatide Once Weekly for the Treatment of Obesity.
18. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
19. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
20. Semaglutide.
21. Wegovy, INN-semaglutide – Product Information.
22. Semaglutide: a medicine to manage type 2 diabetes or obesity.

Frequently Asked Questions